Global Formulation Development Outsourcing Market by Service (Preformulations, Formulation Development), By Formulation (Oral, Injectable, Topical, Inhaled), By Application (Oncology, Infectious Diseases, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology), By End-User (Pharmaceutical Industries, Research and Academic Institutes, Other End-Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Nov. 2023
- Report ID: 83445
- Number of Pages: 252
- Format:
- keyboard_arrow_up
Quick Navigation
Report Overview
In 2023, the global formulation development outsourcing market accounted for USD 37.2 billion and is expected to grow to around USD 67.7 billion in 2032. Between 2023 and 2032, this market is estimated to register the highest CAGR of 7.1%.
Formulation development outsourcing refers to the industry involved in providing formulation development services to pharmaceutical, biotech, and medical device companies. It includes companies which are specialized in developing and optimizing formulations for drug candidates and companies that provide related services such as analytical testing, regulatory support, and process development. The formulation development outsourcing market growing rapidly due to the increasing complexity of drug formulations.
Note: Actual Numbers Might Vary In The Final Report
Key Takeaways
- Market Growth: The Formulation Development Outsourcing Market was valued at USD 34.7 billion in 2022 and is expected to reach USD 67.7 billion by 2032, with a CAGR of 7.1%.
- Service Segments: Formulation development services hold a significant share, expected to grow at a CAGR of 7.5%, while preformulations are the fastest-growing segment.
- Formulation Types: Oral formulations dominate the market, with a 62.4% share and an expected CAGR of 7.8% in 2022.
- End-User Analysis: Pharmaceutical industries hold a major share (71.5%) in the market, while research and academic institutes are the fastest-growing segment with a projected CAGR of 7.3%.
- Regional Analysis: North America leads the market with a 37.2% revenue share in 2022, with the Asia Pacific expected to be the fastest-growing region at a CAGR of 6.5%.
- Key Players: Market leaders like SGS S.A., Lonza Group AG, and Thermo Fisher Scientific Inc. are focusing on developing and commercializing innovative drugs.
- Market Drivers: Growing demand for innovative drugs, cost reduction, and the rise of chronic diseases are driving market growth.
- Market Restraints: Intellectual property concerns and quality issues are hindering the market’s growth.
- Market Opportunities: There is an increasing demand for specialized expertise, cost-effective solutions, and access to advanced technologies, especially in emerging economies.
Service Analysis
The Formulation Development Segment is The Most Lucrative Segment in The Product Type of Formulation Development Outsourcing Market.
Based on service, the market for formulation development outsourcing is segmented into formulations and formulation development. Among these types, the formulation development segment is the most lucrative in the global formulation development outsourcing market, with a projected CAGR of 7.5%. The total revenue share of formulation development type formulation development outsourcing is 76.8% in 2022. It involves designing and optimizing the final dosage form of a drug, like capsules, tablets, and injectables, to ensure drug delivery and bioavailability. This can also include activities such as optimizing formulation parameters.
The Pre-Formulation Service is Expected to Grow in the Projected Period in Formulation Development Outsourcing Market.
Followed by pre-formulation service, which accounted for the fastest-growing type segment in the formulation development outsourcing market, and its estimated market share is 23.2% in 2022. The pre-formulation is often conducted early in the drug development process to evaluate the physicochemical properties of a drug candidate and determine the optimal formulation strategy.
Formulation Analysis
The Oral Segment Holds the Majority Share in the Technology Segment of the Formulation Development Outsourcing Market.
By formulation, the market is further divided into oral, injectable, topical, and inhaled. Among these, the oral segment is estimated to be the most lucrative segment in the global formulation development outsourcing market, with a market share of 62.4% and a projected CAGR of 7.8%, in 2022. Owing to oral delivery being the most common route of administration for pharmaceuticals, oral formulations are relatively easy to develop compared to other routes of administration like inhalation or injection.
The Injectable Segment is Expected as Fastest Growing Technological Segment in Formulation Development Outsourcing Market.
Also, the injectable segment is estimated as the fastest-growing segment in technology with a CAGR of 7.2. Owing to its increasing demand for biologics, growing demand for targeted delivery, technological advancements, and favorable regulatory environments.
Application Analysis
The Oncology Segment Accounted for the Largest Revenue Share in Formulation Development Outsourcing Market in 2022.
Based on application, the market is segmented into oncology, infectious diseases, neurology, hematology, respiratory, cardiovascular, and dermatology. Among these, the oncology segment is estimated to be the most lucrative segment in the global formulation development outsourcing market, with the largest revenue share of 28.8% and a projected CAGR of 7.6% during the forecast period. Owing to its high demand, complex formulations, regulatory requirements, high-profit margins, and increasing prevalence of cancer worldwide.
The Infectious Diseases Segment is Expected to be the Fastest Growing Application Segment in Formulation Development Outsourcing Market.
The infectious diseases segment is projected as the fastest-growing application segment in the Formulation Development Outsourcing market, with a revenue share of 22.4% in 2022, and registering a CAGR of 7.2% from 2022 to 2031. This segment has gained importance due to the COVID-19 pandemic. The pandemic has led to an increase in demand for antiviral drugs, vaccines, and other treatments for infectious diseases is continue to grow due to the need for innovative solutions to tackle viral and bacterial infections.
End-User Analysis
The Pharmaceutical Industries Development Outsourcing Companies Hold the Significant Share of the End-User Segment in Formulation Development Outsourcing Market.
Based on end-user, the market is divided into pharmaceutical industries and research and academic institutes. Among these end-users, pharmaceutical industries are dominant in the end-user segment in the formulation development outsourcing market, with a market share of 71.5% and a CAGR of 7.8. This is due to the pharmaceutical industries being the largest consumers of formulation development outsourcing services. There is also high demand for new drugs and pharmaceutical industries are focused on developing new drugs to tackle a number of diseases and conditions.
Research and Academic Institute is Identified as Fastest Growing End-User Segment in Projected Period.
Research and academic institutes is also important end-user segment in the formulation development outsourcing market and it is expected to grow faster in the end-user segment in the Formulation Development Outsourcing market with a CAGR of 7.3 and a market value is 22.8%. This is the fastest-growing end-user segment because of its increasing focus on translational research, budget constraints, and collaboration with industry.
Note: Actual Numbers Might Vary In The Final Report
Key Market Segments
Based on Service
- Preformulations
- Formulation Development
Based on Formulation
- Oral
- Injectable
- Topical
- Inhaled
- Other Outlooks
Based on Application
- Oncology
- Infectious Diseases
- Neurology
- Hematology
- Respiratory
- Cardiovascular
- Dermatology
- Other Applications
Based on End-User
- Pharmaceutical Industries
- Research and Academic Institutes
- Other End-Users
Drivers
Growing Demand for New and Innovative Drugs, Cost Reduction, and Increasing Prevalence of Chronic Diseases Drive the Market Growth of the Formulation Development Outsourcing Market.
The factors which drive the formulation development outsourcing market includes, increasing demand for new and innovative drugs to tackle a wide range of diseases and conditions, the formulation development outsourcing services help pharmaceutical companies to increase the drug development process and introduce new drugs to market quickly and efficiently.
Drug development is a complex and costly process that requires significant investment in R&D, formulation development outsourcing services can help pharmaceutical industries reduce costs. Advancements in technology such as 3D printing, biotechnology, and nanotechnology have revolutionized drug development and formulation, formulation development outsourcing can help pharmaceutical industries to take advantage of these advancements to develop new drugs.
The increasing prevalence of chronic diseases like diabetes, cancer, and cardiovascular diseases, are driving the demand for new and improved treatments. Drug development is subject to strict regulatory requirements and ensuring compliance with these requirements is vital for introducing new drugs into the market. Biologics and biosimilars are complex drugs that require hence formulation development outsourcing services that can help pharmaceutical industries to develop drugs more cost-effectively.
Restraints
Intellectual Property Concerns, Quality Concerns, Communication and Coordination Issues, and Political and Economic Instability are Some Restraints to Formulation Development Outsourcing Market.
Formulation development outsourcing also has some restraints in the global market, which affect the growth of the formulation development outsourcing market. The factors include intellectual property concerns, as it is critical to maintaining a competitive advantage. Lack of control over the drug development process. Quality concerns occur when a provider does not have the necessary expertise.
Communication and coordination issues occur when the service provider is located in another country. Political and economic instability may increase the risk of supply chain disruptions, which can negatively impact the growth of the Formulation Development Outsourcing market.
Opportunity
Increasing Demand for Specialized Expertise, Cost-effective solutions, and access to cutting-edge technologies Creates Opportunities in the Formulation Development Outsourcing market.
The formulation development outsourcing industry is also boosted due to growing healthcare industries in several emerging economies such as Brazil, India, South Africa, and China. There are some opportunities in this sector like increasing demand for specialized expertise such as drug delivery, controlled release systems, and nanoparticle formulation.
Pharmaceutical industries are playing a vital role in the formulation development outsourcing market by focusing and innovating on oncology formulation development and other drug development. Moreover, the adoption of new methods availability and pharmaceutical services by key market players increase the market size during the forecasted period.
However, key players are capturing maximum profit in the market by accepting some marketing tactics and methodologies. The pharmaceutical company’s hunt for novel and efficient medicines continues to be longer-term growth and clinical research for both existing COVID-19 and new medications.
Trends
An increase in Demand for Complex and Specialized Formulations, Growing Focus on Risk-Sharing Partnerships are Some Recent Trends in Formulation Development Outsourcing Market.
The growing prevalence of chronic diseases like cancer, arthritis, asthma, diabetes, chronic obstructive pulmonary disease, and Alzheimer’s is producing the demand for the finding and development of new drugs. This represents one of the major factors resulting in the formulation development services being outsourced to contract research organizations around the world.
Outside of this, there is an increase in the requirement to overcome the risk and save the money and time invested in passing the drug through the development pipeline. Growing focus on risk-sharing partnerships which allows pharmaceutical companies to share the cost and risk of drug development with outsourcing partners. Expansion of services offered by CROs and CDMOs to provide end-to-end solutions from drug finding to commercialization.
Regional Analysis
North America Accounted for the Largest Revenue Share in Formulation Development Outsourcing Market in 2022.
North America is estimated to be the most lucrative market in the global formulation development outsourcing market, with the largest market share of 37.2%, and is expected to register a CAGR of 7.1% during the forecast period. Owing to the presence of a large number of pharmaceutical and biotechnology industries, well-established health infrastructure, availability of specialized expertise in drug delivery, and favorable regulatory environment. The region’s expectations for formulation development outsourcing are expanding because of an increase in the number of approved drugs and the development of the vaccine.
APAC is expected as Fastest Growing Region in Projected Period in Formulation Development Outsourcing Market.
Asia Pacific is expected as fastest growing region in the Formulation Development Outsourcing market with a CAGR of 6.5% and a market value of 25.3%. Owing to its increase in the number of biotechnology and pharmaceutical companies. Rising healthcare expenditure, and growing demand for generic drugs. Also, countries like India and China have become charming destinations due to the availability of skilled labor, supportive regulatory environment, and lower costs.
Note: Actual Numbers Might Vary In The Final Report
Key Regions and Countries Covered in this Report:
- North America
- The US
- Canada
- Europe
- Germany
- France
- The UK
- Spain
- Italy
- Russia
- Netherland
- Rest of Europe
- APAC
- China
- Japan
- South Korea
- India
- Australia
- New Zealand
- Singapore
- Thailand
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
Key Players Analysis
Emerging key players are focused on the development and commercialization of new and innovative drugs. For example, Catalent Inc. is leading advanced delivery technologies, manufacturing solutions for drugs, gene therapies, consumer health products, and development. Lonza Group Ltd. is a Swiss MNC that provides products and series to the biotechnology, specialty ingredients market, and pharmaceutical. Thermo Fisher Scientific is a global leader in the development and manufacture of analytical instruments, consumables, and services for research, diagnostic, analysis, software, and reagents.
Market Key Players
- SGS S.A.
- Intertek Group plc.
- Recipharm AB
- Lonza Group AG
- Charles River Laboratories International Inc.
- Eurofins Scientific SE
- Element
- Labcorp
- Thermo Fisher Scientific Inc.
- Catalent Inc.
- Laboratory Corporation of America
- Intertek
- Quotient Sciences
- Reddy’s Laboratories
- Emergent Biosolutions Inc.
- Aizant Drug Research Solutions Pvt. Ltd.
- Other Key Players
Recent Developments
- In June 2022, Lonza started a new R&D facility in Bend dedicated to supporting early-phase clinical trials.
- In April 2022, Labcorp collaborated with a developer of cell and gene therapy technologies to expand its research capabilities in cell and gene therapies.
- In January 2021, Lonza announced the expansion of its formulation development capabilities in Europe by starting a new facility in Basel, Switzerland. The facility can strengthen the firm’s expertise in lipid nanoparticle technology for the delivery of RNA-based therapeutics.
Report Scope
Report Features Description Market Value (2023) US$ 37.2 Bn Forecast Revenue (2032) US$ 67.7 Bn CAGR (2023-2032) 7.1% Base Year for Estimation 2022 Historic Period 2016-2022 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered by Service (Preformulations, Formulation Development), By Formulation (Oral, Injectable, Topical, Inhaled), By Application (Oncology, Infectious Diseases, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology), By End-User (Pharmaceutical Industries, Research and Academic Institutes, Other End-Users) Regional Analysis North America – The U.S. & Canada; Europe – Germany, France, The UK, Spain, Italy, Russia, Netherlands & Rest of Europe; APAC- China, Japan, South Korea, India, Australia, New Zealand, Singapore, Thailand, Vietnam & Rest of APAC; Latin America- Brazil, Mexico & Rest of Latin America; Middle East & Africa- South Africa, Saudi Arabia, UAE & Rest of MEA Competitive Landscape SGS S.A., Intertek Group plc., Recipharm AB, Lonza Group AG, Charles River Laboratories International Inc., Eurofins Scientific SE, Element, Labcorp, Thermo Fisher Scientific Inc., Catalent Inc., Laboratory Corporation of America, Intertek, Quotient Sciences, Reddy’s Laboratories, Emergent Biosolutions Inc., Aizant Drug Research Solutions Pvt. Ltd., Other Key Players Customization Scope Customization for segments and region/country level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) Frequently Asked Questions (FAQ)
What is formulation development outsourcing, and how does it impact the pharmaceutical industry?Formulation development outsourcing involves the delegation of pharmaceutical formulation research and development activities to external service providers. Pharmaceutical companies can utilize expertise, reduce costs, and accelerate drug formulation development - thus spurring innovation and hastening market delivery of new therapies.
How big is formulation development outsourcing market?In 2023, the global formulation development outsourcing market accounted for USD 37.2 billion and is expected to grow to around USD 67.7 billion in 2032. Between 2023 and 2032, this market is estimated to register the highest CAGR of 7.1%.
Which segment accounted for the largest formulation development outsourcing market share?North America Accounted for the Largest Revenue Share in Formulation Development Outsourcing Market in 2022.
What are the factors driving the growth of the formulation development outsourcing market?The formulation development outsourcing market is primarily driven by factors such as the increasing complexity of drug formulations, the rising demand for specialized expertise in formulation technologies, the need for accelerated time-to-market for pharmaceutical products, and the emphasis on cost optimization and risk mitigation in the drug development process. Additionally, the growing prevalence of chronic diseases and the expansion of the generic and biopharmaceutical sectors are further fueling the demand for formulation development outsourcing services.
Formulation Development Outsourcing MarketPublished date: Nov. 2023add_shopping_cartBuy Now get_appDownload Sample - SGS S.A.
- Intertek Group plc.
- Recipharm AB
- Lonza Group AG Company Profile
- Charles River Laboratories International Inc.
- Eurofins Scientific SE
- Anglo American Plc Company Profile
- Labcorp
- Thermo Fisher Scientific Company Profile
- Catalent Inc.
- Laboratory Corporation of America
- Intertek
- Quotient Sciences
- Dr. Reddys Laboratories Ltd Company Profile
- Emergent Biosolutions Inc.
- Aizant Drug Research Solutions Pvt. Ltd.
- Other Key Players
- settingsSettings
Our Clients
Single User $6,000 $3,999 USD / per unit save 24% | Multi User $8,000 $5,999 USD / per unit save 28% | Corporate User $10,000 $6,999 USD / per unit save 32% | |
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |